Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: Colorectal Neoplasms trials
The registry lists 11 Colorectal Neoplasms studies with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 1 2Phase 2 8No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.RecruitingNCT04689347Phase 1/2
- Liquid Biopsy Biomarkers for Endoscopic Surveillance in Lynch SyndromeCompletedNCT07838246
- Familial Adenomatous Poliposys Italian Network (Rete Italiana Poliposi Adenomatosa Familiare)Active, not recruitingNCT07461246
- Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant ChemotherapyStatus unknownNCT05031975Phase 2
- NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerCompletedNCT03832621Phase 2
- Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver TransplantationCompletedNCT03803436Phase 2
- Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk PatientsCompletedNCT02575859Phase 1/2
- Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)Status unknownNCT02476045Phase 2
- Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer PatientsCompletedNCT02414009Phase 2
- PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASESCompletedNCT02086656Phase 2
- Colorectal Cancer Detection by Means of Optical FluoroscopyStatus unknownNCT01286064Not applicable